This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Humicade, BAY103356, BAYW3356
Description: Like Enbrel, Remicade, and Humira, CDP571 blocks the ability of TNFa to bind to its receptor.
Deal Structure: Celltech originally partnered with Bayer to develop CDP571. In April 2002, however, Celltech announced a collaboration with Biogen to develop CDP571.
Partners: Biogen, Inc.
Additional information available to subscribers only: